12 Mar 2007 -
ARIUS Research Inc. announced that it has been granted two new United States patents for antibodies within their CD63 program. Patent 7,175,846. covers anti-cancer antibodies in ARIUS' partnered program for melanoma, breast and prostate cancers and protects the valuable site on the disease target that the drug candidate binds to. The Company's FunctionFIRST(TM) platform uses a unique process to discover antibody drugs by identifying those that destroy cancer cells while leaving normal cells alone. In the process the antibodies can attach themselves to the cancer cell but they must hit the appropriate spot on the cell i.e. the "target on the target", in order to destroy it. ARIUS' patent strategy has successfully captured the discovery process, the antibody drug molecules and now the spot on the target that is key to causing the cancer cell's destruction.
Patent 7,186,808 covers a second antibody within this program that kills breast and prostate cancer cells. The patent also covers the use of the antibody as a treatment for breast cancer.
Top
Contact
Print version
Send article
RSS feed